FindTrial
Sign In

AZD0530

DRUG9 trials

Sponsors

Stichting Amsterdam UMC, NCIC Clinical Trials Group, AstraZeneca

Conditions

Bone NeoplasmsBreast CancerCancerEpithelial Ovarian CancerFibrodyplasia Ossificans Progressiva (FOP)HealthyNeoplasmsNon Small Cell Lung Cancer

Phase 1

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
CompletedNCT00265876
NCIC Clinical Trials GroupPancreatic Cancer
Start: 2006-04-26End: 2012-01-06Updated: 2023-08-04
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
CompletedNCT00475956
AstraZenecaNeoplasms
Start: 2007-05-31End: 2009-10-31Updated: 2010-04-15
Phase I Study in Patients With Solid Tumours
CompletedNCT00496028
AstraZenecaNeoplasms
Start: 2007-03-31End: 2010-03-31Updated: 2010-09-22
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
CompletedNCT00704366
AstraZenecaSolid Tumor
Start: 2008-06-30End: 2011-05-31Updated: 2011-05-16
Relative Bioavailability of Phase II and Phase III Formulations of AZD0530
CompletedNCT00771979
AstraZenecaHealthy
Start: 2008-11-30End: 2009-03-31Updated: 2009-06-18
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
WithdrawnNCT01000896
AstraZenecaCancer, Epithelial Ovarian Cancer, Non Small Cell Lung Cancer
Start: 2010-01-31End: 2011-03-31Target: 27Updated: 2010-02-04

Phase 2

Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
CompletedNCT00558272
AstraZenecaBone Neoplasms, Breast Cancer, Prostate Cancer
Start: 2008-02-29End: 2012-08-31Updated: 2013-05-27
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
CompletedNCT00610714
AstraZenecaOvarian Cancer, Ovarian Neoplasms
Start: 2008-04-30End: 2012-01-31Updated: 2012-12-18
Saracatinib trial TO Prevent FOP (STOPFOP)
Active, not recruitingCTIS2024-515186-33-00
Stichting Amsterdam UMCFibrodyplasia Ossificans Progressiva (FOP)
Start: 2020-01-08Target: 18Updated: 2025-12-01

Related Papers

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
2012-03-1422 citations